Earnings summaries and quarterly performance for MAIA Biotechnology.
Executive leadership at MAIA Biotechnology.
Board of directors at MAIA Biotechnology.
Research analysts covering MAIA Biotechnology.
Recent press releases and 8-K filings for MAIA.
MAIA Biotechnology Announces Private Placement
MAIA
Equity Offering
New Projects/Investments
- MAIA Biotechnology, Inc. announced a private placement on December 16, 2025, which is expected to close on or about December 18, 2025.
- The company will sell an aggregate of 1,233,488 shares of common stock at a purchase price of $1.224 per share, with each share offered together with a warrant to purchase one share of common stock at an exercise price of $1.36 per share.
- The gross proceeds from the offering are expected to be approximately $1.51 million.
- The net proceeds will be used to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
- The private placement includes participation from accredited investors and a Company director, with 179,737 shares and corresponding warrants issued to directors under the Company's 2021 Equity Incentive Plan.
6 days ago
MAIA Biotechnology Leadership Continues Insider Buying Amidst Encouraging Trial Data
MAIA
New Projects/Investments
- MAIA Biotechnology's CEO, Dr. Vlad Vitoc, and other board members acquired approximately 182,445 shares between November 21 and 28, 2025.
- This insider buying reflects confidence in the ateganosine platform, which is showing encouraging results in mid- to late-stage clinical development for advanced non-small cell lung cancer (NSCLC).
- Directors and Officers collectively hold 4,480,120 shares, representing 12.95% of the company.
Dec 11, 2025, 9:15 PM
MAIA Biotechnology Initiates Pivotal Phase 3 Trial for Ateganosine
MAIA
New Projects/Investments
- MAIA Biotechnology has initiated a pivotal Phase 3 program for its first-in-class telomere-targeting therapy, ateganosine (THIO), for advanced non-small cell lung cancer (NSCLC), with the Phase 2 trial still ongoing.
- Ateganosine is described as the only direct telomere-targeting anticancer agent currently in clinical development and has received U.S. FDA Fast Track designation for NSCLC.
- The therapy works through a dual mechanism of action that differentiates it from existing treatments, involving selective incorporation into cancer-cell telomeres and triggering an immunogenic response.
- Management indicates a very high probability of technical success for regulatory approval of ateganosine based on statistical assessments of the Phase 3 trial.
Dec 11, 2025, 6:00 PM
MAIA Biotechnology Reports Insider Share Purchases and Clinical Progress
MAIA
New Projects/Investments
- MAIA Biotechnology's CEO, Dr. Vlad Vitoc, and other board members acquired approximately 182,445 shares between November 21 and 28, 2025, demonstrating confidence in the company's ateganosine platform.
- The company's lead program, ateganosine, a telomere-targeting cancer therapy, is advancing through mid- to late-stage clinical development and continues to deliver encouraging results for non-small cell lung cancer (NSCLC).
- Directors and Officers of MAIA Biotechnology collectively hold 4,480,120 shares, representing 12.95% of the company.
Dec 11, 2025, 1:00 PM
MAIA Biotechnology Highlights Telomere-Targeting Agent Ateganosine and Market Opportunity
MAIA
New Projects/Investments
- MAIA Biotechnology is developing ateganosine, a potential first-in-class telomere-targeting agent for advanced non-small cell lung cancer (NSCLC) patients who are resistant to existing immunotherapies and chemotherapy.
- Ateganosine has received Fast Track Designation from the U.S. FDA for NSCLC and is initiating a Phase 3 THIO-104 trial.
- The NSCLC market is valued at $34.1 billion, projected to reach $68.8 billion by 2033, and ateganosine also holds FDA Orphan Drug Designations for Glioblastoma, Hepatocellular carcinoma, and Small cell lung cancer, offering seven years of U.S. market exclusivity upon regulatory approval.
Dec 10, 2025, 9:15 PM
MAIA Biotechnology Highlights Ateganosine Clinical Program Progress at SITC 2025
MAIA
New Projects/Investments
- MAIA Biotechnology highlighted the ongoing momentum of its Ateganosine clinical program at SITC 2025, covering Phase 2 THIO-101 and Phase 3 THIO-104 clinical trials for non-small cell lung cancer (NSCLC).
- The company reported 12 patients enrolled in the Phase 2 THIO-101 expansion trial, with enrollment expanding to European Medicines Agency countries, Turkey, and Taiwan.
- Patient screening has also begun for the Phase 3 THIO-104 trial.
- Ateganosine holds Fast Track designation from the U.S. FDA for NSCLC.
- The Phase 2 THIO-101 trial has demonstrated an overall survival (OS) of 17.8 months to date, compared to approximately 6 months for current third-line NSCLC treatments, with one patient showing survival of 30 months (912 days) as of September 17, 2025.
Nov 21, 2025, 2:15 PM
MAIA Biotechnology Expands Phase 2 THIO-101 Study to Romania for NSCLC Treatment
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. announced on November 20, 2025, that it has initiated patient enrollment in Romania for the Phase 2 THIO-101 Part C study.
- This study evaluates ateganosine as a third-line treatment for advanced non-small cell lung cancer (NSCLC) patients.
- CEO Vlad Vitoc, M.D., highlighted observed 38% response rates with ateganosine treatment, significantly surpassing the up to 6% response rates of current treatments for this patient population.
- The expansion of the study to Romania aims to accelerate patient access and supports the company's strategy for accelerated approval in the U.S., following the FDA's Fast Track Designation received in July.
Nov 20, 2025, 2:00 PM
MAIA Biotechnology Announces Private Placement
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. announced a private placement involving the sale of 603,769 shares of common stock at a purchase price of $1.22 per share.
- Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.52 per share.
- The private placement is expected to generate approximately $736,600 in gross proceeds.
- The company intends to use the net proceeds from the offering to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
- The closing of the private placement is anticipated on or about October 15, 2025.
Oct 14, 2025, 1:00 PM
MAIA Biotechnology Announces $736,600 Private Placement
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. has entered into definitive agreements for a private placement of 603,769 shares of common stock at a purchase price of $1.22 per share.
- Each share of common stock is offered with a warrant to purchase one share at an exercise price of $1.52 per share, exercisable six months after issuance for a term of three years.
- The offering is expected to generate approximately $736,600 in gross proceeds.
- The net proceeds will be used to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
Oct 13, 2025, 8:20 PM
MAIA Biotechnology announces digital asset treasury strategy
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. announced on October 7, 2025, the launch of a new digital asset treasury strategy focused on top-tier cryptocurrency assets.
- The company's Board of Directors has authorized holding up to 90% of its liquid assets in various cryptocurrencies.
- The initial cryptocurrencies approved for purchase and sale are Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC).
- This strategy aims to diversify the investment portfolio and create shareholder value for shareholders.
Oct 7, 2025, 12:58 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more